{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:57:34Z","timestamp":1781135854865,"version":"3.54.1"},"reference-count":66,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Multiple sclerosis (MS) biomarkers hold potential for improving pathophysiological understanding, diagnostics, prognostication, and treatment personalisation. Technological advances now permit detection of blood biomarkers at previously prohibitively low concentrations. Concentrations of several candidate biomarkers have been shown to correlate between blood and cerebrospinal fluid (CSF). The development of \u2018-omics\u2019 panel-based technologies now facilitates the discovery of collections of molecules, the interdependency of which may better reflect disease heterogeneity. Neurofilament light (NfL) is the clearest example of the success of a biomarker entering the realm of clinical practice in MS, with promising developments in others such as glial fibrillary acid protein (GFAP). However, integration of new biomarkers requires standardisation of discovery and validation across the various available technologies, along with demonstration of clinical utility, to gain regulatory approval and widespread adoption. In this review, focused on blood-based biomarkers, we expand on the above discoveries, developments and trajectories, to provide a framework for understanding this crucial body of work.<\/jats:p>","DOI":"10.1177\/13524585261432045","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T07:30:31Z","timestamp":1774855831000},"page":"661-669","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A framework for blood biomarker discovery in MS"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3760-6634","authenticated-orcid":false,"given":"Emma C","family":"Tallantyre","sequence":"first","affiliation":[{"name":"Division of Psychological Medicine and Clinical Neuroscience, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3399-7823","authenticated-orcid":false,"given":"Sean","family":"Apap Mangion","sequence":"additional","affiliation":[{"name":"Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, Institute of Neurology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-0837","authenticated-orcid":false,"given":"Charlotte E","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC, VU University Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200370"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61751-9"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.787160"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24954"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00009-6"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007032"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104662"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67504-6"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-328568"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104970"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241277044"},{"key":"e_1_3_2_13_2","article-title":"Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis","volume":"10","author":"Barro C","year":"2025","unstructured":"Barro C, Healy BC, Liu Y, et al. Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2025; 10: e200052.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518819380"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.5250"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51969"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae260"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251375780"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251358339"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251335521"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231188625"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2025-335831"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-022-03060-6"},{"key":"e_1_3_2_24_2","article-title":"Role of chitinase 3\u2013like 1 as a biomarker in multiple sclerosis","volume":"9","author":"Floro S","year":"2025","unstructured":"Floro S, Carandini T, Pietroboni AM, et al. Role of chitinase 3\u2013like 1 as a biomarker in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2025; 9: e1164.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516639384"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1343892"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83591-5"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42682-9"},{"key":"e_1_3_2_29_2","first-page":"410","article-title":"Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis","volume":"95","author":"Fissolo N","year":"2024","unstructured":"Fissolo N, Benkert P, Sastre-Garriga J, et al. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2024; 95: 410.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03036-4"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2016.12.006"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-020-0170-5"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/09612033251319405"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200050"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/2051-5960-2-53"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1007102"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2010.03.014"},{"key":"e_1_3_2_38_2","article-title":"Association of complement factors with disability progression in primary progressive multiple sclerosis","volume":"11","author":"Lunemann JD","year":"2025","unstructured":"Lunemann JD, Hegen H, Villar LM, et al. Association of complement factors with disability progression in primary progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2025; 11: e200270.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512438238"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103922"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-019-01856-7"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0314428"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq035"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1021\/pr3012107"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade8560"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03926-3"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.771"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1579045"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51990"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1912839117"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.9967.2"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac420"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/prca.202200018"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48602-9"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109688"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad300"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-016-0257-9"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207459"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.637"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14090493"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2123265119"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26189207"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001004"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517696597"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14301-3"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24931"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00588"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261432045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585261432045","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585261432045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:16:12Z","timestamp":1781133372000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585261432045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/13524585261432045"],"URL":"https:\/\/doi.org\/10.1177\/13524585261432045","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]}}}